ImmuPharma: ImmuPharma can't explain near-400% stock jump
Specialist drug discovery and development outfit ImmuPharma has said that it can't pinpoint a reason behind its share price more than quadrapling over the past month.
Read full article »
ImmuPharma develops drug components for lupus, cancer, pain relief, MRSA and inflammatory diseases.
Read more